Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 13, Issue 2, Pages 713-722Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2016.10.005
Keywords
Aptide; Multi-drug resistance; Extra-domain B ( EDB) of fibronectin; siRNA; Drug delivery; Liposomes
Funding
- Global Research Laboratory through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2015045887]
- David H. Koch-PCF Program in Cancer Nanotherapeutics
- National Research Foundation of Korea [2012K1A1A2045436] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Amajor problem with cancer chemotherapy begins when cells acquire resistance. Drug-resistant cancer cells typically upregulatemulti-drug resistance proteins such as P-glycoprotein (P-gp). However, the lack of overexpressed surface biomarkers has limited the targeted therapy of drug-resistant cancers. Here we report a drug-delivery carrier decoratedwith a targeting ligand for a surface marker protein extra-domain B(EDB) specific to drug-resistant breast cancer cells as a new therapeutic option for the aggressive cancers. We constructed EDB-specific aptide (APT(EDB))-conjugated liposome to simultaneously deliver siRNA(siMDR1) andDox to drug-resistant breast cancer cells. APT(EDB)-LS(Dox, siMDR1) led to enhanced delivery of payloads intoMCF7/ADR cells and showed significantly higher accumulation and retention in the tumors. While either APT(EDB)-LS(Dox) or APT(EDB)-LS(siMDR1) did not lead to appreciable tumor retardation in MCF7/ADR orthotropic model, APT(EDB)-LS(Dox, siMDR1) treatment resulted in significant reduction of the drugresistant breast tumor. Taken together, this study provides a new strategy of drug delivery for drug-resistant cancer therapy. (C)2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available